Skip to main content

Table 3 Endpoints and outcomes

From: Evaluation of early antimicrobial therapy adaptation guided by the BetaLACTA® test: a case-control study

  All patients Conventional adaptation strategy BLT-guided adaptation strategy p
(n = 122) (n = 61) (n = 61)  
Appropriate empirical antimicrobial therapy, % (n) 80% (98) 77% (47) 84% (51) 0.45
Early escalation, % (n) 7% (9) 0% (0) 15% (9) <0.01*
Appropriate antimicrobial therapy after culture results, % (n) 88% (107) 77% (47) 98% (60) <0.01
Delay before antimicrobial therapy escalation (h) 48 (28–60) 50.5 (48–73) 27 (24–28) <0.01#
Optimal empirical antimicrobial therapy, % (n) 51% (62) 46% (28) 56% (34) 0.33
Early adaptation, % (n) 22% (27) 2% (1) 43% (26) <0.01*
escalation 7% (9) 0% (0) 15% (9)  
de-escalation 15% (18) 2% (1) 28% (17)  
Optimal antimicrobial therapy after culture results, % (n) 71% (87) 48% (29) 95% (58) <0.01
Delay before antimicrobial therapy adaptation (h) 49 (31.5–65) 58 (48–72) 28 (24.5–47) <0.01#
Time to apyrexia (h) 24 (24–72) 24 (24–48) 30 (24–72) 0.19#
Time to leukocytosis <10.000/mm3 (days) 6 (3–13) 5 (3–12) 6 (3–15) 0.37#
Time to mechanical weaning (days) 5 (3–9) 4.5 (3–9) 5 (4–8) 0.51#
Length of ICU stay (days) 10 (5–16) 11 (6–17) 10 (5–15) 0.48
Mortality, % (n) 15% (18) 16% (10) 13% (8) 0.80
  1. BLT BetaLACTA® test
  2. *Fisher exact test was used due to multiple categorical variables
  3. #Wilcoxon test (non-paired) was used due to data not present for patients without antimicrobial escalation/adaptation, or for patients who had never been febrile, had hyperleukocytosis, nor been ventilated